Severe obesity tied to weakened heart muscle in HFpEF patients: Circulation

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2021-01-08 10:28 GMT   |   Update On 2021-01-09 08:29 GMT

USA: Greater obesity weakens contraction of heart muscle in patients having heart failure with a preserved ejection fraction (or HFpEF), suggests a recent study in the journal Circulation. The findings challenges the common notion that the disease is all about having a stiff heart that cannot relax.

HFpEF, a common type of heart failure that occurs in about half of the heart failure patients, is characterized by normal contraction of heart. This was first seen primarily in elderly, slim women having high blood pressure and thicker heart muscle. However, with the increase in incidence of diabetes and obesity, many HFpEF patients are now found to be severely obese with BP not as high and heart muscle not as thick as was seen in previous patients.

The study was performed by David Kass, the Abraham and Virginia Weiss Professor of Cardiology at the Johns Hopkins University School of Medicine, and colleagues. 

"Obesity would seem to have changed the heart muscle," says Kass. "The "p" in HFpEF stands for preserved, and that's what contraction was supposed to be, and what HFpEF used to be. But, as more patients are obese and our results show this reduces contraction strength, we will need to rethink our concepts and along with it, our treatments."

Advertisement

Traditionally, this form of heart failure has been treated with medicines that often reduce contraction strength while improving the heart's relaxation. Further research, Kass says, will need to determine if this approach needs to be modified.

As part of the evaluation of patients with HFpEF, a tiny piece of heart muscle is collected using a standard heart biopsy procedure. The biopsy samples taken from patients who were less obese (a body mass index, or BMI, averaging 30) but had high blood pressure and thick heart muscle were compared with those with severe obesity (BMI averaging 40) but lower blood pressure and less thick heart muscle. The investigators teased out single muscle cells from these samples and studied their function. When the researchers added calcium to stimulate the cells to contract, those from the less-obese group responded normally.

However, the force response to high calcium was reduced by 40% in cells from patients with obesity. In a third group of patients who had both high blood pressure and thicker hearts, as well as severe obesity, the force response in the cells given calcium was similarly reduced as in the mostly obese group. Kass and his colleagues believe this points to obesity as the key factor.

HFpEF was previously called diastolic heart failure, emphasizing the idea that although the heart could contract normally, it didn't properly fill with blood when the heart relaxed in preparation for the next beat (called diastole). While preserved contraction appears still true for less obese patients with high blood pressure and thick heart muscle, it doesn't appear to hold true when they also have severe obesity.

Severe obesity alters underlying human biology—most recently brought in focus with the COVID-19 pandemic as obesity has been shown to be an independent risk factor for more severe disease and worse outcome. Many of COVID-19's effects on artery function, the immune system and inflammation, and metabolism and heart stress may also be relevant to HFpEF, the researchers say.

"We do not yet know why this reduced force happens," says Kass. "But, we are trying to figure it out with the goal of testing new and different drugs to improve contraction and personalize treatment for our patients with HFpEF and obesity."

The study titled, "Reduced Right Ventricular Sarcomere Contractility in HFpEF with Severe Obesity," is published in the journal Circulation.

DOI: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.052414

Tags:    
Article Source : Circulation

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News